PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
NYSE:PBH - US74112D1019 - Common Stock
68.04 USD
+0.78 (+1.16%)
69.08 USD
+1.04 (+1.53%)
PBH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. PBH has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. PBH has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
PBH had positive earnings in the past year.
PBH had a positive operating cash flow in the past year.
Of the past 5 years PBH 4 years were profitable.
In the past 5 years PBH always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 6.31%, PBH belongs to the top of the industry, outperforming 90.16% of the companies in the same industry.
PBH's Return On Equity of 11.70% is amongst the best of the industry. PBH outperforms 87.05% of its industry peers.
With an excellent Return On Invested Capital value of 8.02%, PBH belongs to the best of the industry, outperforming 84.46% of the companies in the same industry.
PBH had an Average Return On Invested Capital over the past 3 years of 8.16%. This is significantly below the industry average of 15.38%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.31% | ||
| ROE | 11.7% | ||
| ROIC | 8.02% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
PBH's Profit Margin of 18.86% is amongst the best of the industry. PBH outperforms 92.75% of its industry peers.
In the last couple of years the Profit Margin of PBH has grown nicely.
PBH's Operating Margin of 30.70% is amongst the best of the industry. PBH outperforms 94.82% of its industry peers.
In the last couple of years the Operating Margin of PBH has remained more or less at the same level.
Looking at the Gross Margin, with a value of 55.76%, PBH is in the better half of the industry, outperforming 65.28% of the companies in the same industry.
PBH's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.7% | ||
| PM (TTM) | 18.86% | ||
| GM | 55.76% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PBH is destroying value.
PBH has less shares outstanding than it did 1 year ago.
The number of shares outstanding for PBH has been reduced compared to 5 years ago.
PBH has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.70 indicates that PBH is not a great score, but indicates only limited risk for bankruptcy at the moment.
PBH has a Altman-Z score of 2.70. This is in the better half of the industry: PBH outperforms 70.98% of its industry peers.
PBH has a debt to FCF ratio of 4.17. This is a neutral value as PBH would need 4.17 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.17, PBH belongs to the top of the industry, outperforming 85.49% of the companies in the same industry.
A Debt/Equity ratio of 0.55 indicates that PBH is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.55, PBH is not doing good in the industry: 62.18% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 4.17 | ||
| Altman-Z | 2.7 |
ROIC/WACC0.85
WACC9.42%
2.3 Liquidity
PBH has a Current Ratio of 4.20. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 4.20, PBH is doing good in the industry, outperforming 67.36% of the companies in the same industry.
A Quick Ratio of 2.82 indicates that PBH has no problem at all paying its short term obligations.
PBH's Quick ratio of 2.82 is in line compared to the rest of the industry. PBH outperforms 55.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.2 | ||
| Quick Ratio | 2.82 |
3. Growth
3.1 Past
PBH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.21%, which is quite good.
The Earnings Per Share has been growing by 8.88% on average over the past years. This is quite good.
Looking at the last year, PBH shows a small growth in Revenue. The Revenue has grown by 1.10% in the last year.
Measured over the past years, PBH shows a small growth in Revenue. The Revenue has been growing by 3.39% on average per year.
EPS 1Y (TTM)14.21%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%5.56%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-6.59%
3.2 Future
The Earnings Per Share is expected to grow by 3.32% on average over the next years.
Based on estimates for the next years, PBH will show a small growth in Revenue. The Revenue will grow by 1.15% on average per year.
EPS Next Y0.93%
EPS Next 2Y3.24%
EPS Next 3Y2.71%
EPS Next 5Y3.32%
Revenue Next Year-2.1%
Revenue Next 2Y0.04%
Revenue Next 3Y0.52%
Revenue Next 5Y1.15%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 14.86, PBH is valued correctly.
Based on the Price/Earnings ratio, PBH is valued cheaply inside the industry as 85.49% of the companies are valued more expensively.
PBH's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.08.
A Price/Forward Earnings ratio of 14.09 indicates a correct valuation of PBH.
Based on the Price/Forward Earnings ratio, PBH is valued cheaper than 81.87% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.72, PBH is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.86 | ||
| Fwd PE | 14.09 |
4.2 Price Multiples
86.53% of the companies in the same industry are more expensive than PBH, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, PBH is valued cheaply inside the industry as 87.56% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.76 | ||
| EV/EBITDA | 11.14 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PBH does not grow enough to justify the current Price/Earnings ratio.
PBH has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)16.03
PEG (5Y)1.67
EPS Next 2Y3.24%
EPS Next 3Y2.71%
5. Dividend
5.1 Amount
PBH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
68.04
+0.78 (+1.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners107.49%
Inst Owner Change-0.47%
Ins Owners1.26%
Ins Owner Change5.58%
Market Cap3.35B
Analysts78
Price Target85.27 (25.32%)
Short Float %2.68%
Short Ratio2.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.47%
Min EPS beat(2)0.64%
Max EPS beat(2)4.3%
EPS beat(4)3
Avg EPS beat(4)2.01%
Min EPS beat(4)-0.47%
Max EPS beat(4)4.3%
EPS beat(8)5
Avg EPS beat(8)-0.35%
EPS beat(12)8
Avg EPS beat(12)-46.35%
EPS beat(16)12
Avg EPS beat(16)-31.94%
Revenue beat(2)2
Avg Revenue beat(2)0.9%
Min Revenue beat(2)0.33%
Max Revenue beat(2)1.46%
Revenue beat(4)3
Avg Revenue beat(4)0.74%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)1.57%
Revenue beat(8)3
Avg Revenue beat(8)-0.39%
Revenue beat(12)6
Avg Revenue beat(12)0.09%
Revenue beat(16)10
Avg Revenue beat(16)1.7%
PT rev (1m)-7.93%
PT rev (3m)-6.07%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-5.1%
EPS NY rev (3m)-5.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-3.7%
Revenue NY rev (3m)-3.62%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.86 | ||
| Fwd PE | 14.09 | ||
| P/S | 2.94 | ||
| P/FCF | 13.76 | ||
| P/OCF | 13.31 | ||
| P/B | 1.82 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.14 |
EPS(TTM)4.58
EY6.73%
EPS(NY)4.83
Fwd EY7.1%
FCF(TTM)4.94
FCFY7.27%
OCF(TTM)5.11
OCFY7.51%
SpS23.12
BVpS37.29
TBVpS-20.07
PEG (NY)16.03
PEG (5Y)1.67
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.31% | ||
| ROE | 11.7% | ||
| ROCE | 10.6% | ||
| ROIC | 8.02% | ||
| ROICexc | 8.27% | ||
| ROICexgc | 70.49% | ||
| OM | 30.7% | ||
| PM (TTM) | 18.86% | ||
| GM | 55.76% | ||
| FCFM | 21.38% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexcg growth 3Y-14.1%
ROICexcg growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score7
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 4.17 | ||
| Debt/EBITDA | 2.67 | ||
| Cap/Depr | 27.26% | ||
| Cap/Sales | 0.72% | ||
| Interest Coverage | 7.31 | ||
| Cash Conversion | 66.29% | ||
| Profit Quality | 113.37% | ||
| Current Ratio | 4.2 | ||
| Quick Ratio | 2.82 | ||
| Altman-Z | 2.7 |
F-Score7
WACC9.42%
ROIC/WACC0.85
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.21%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%5.56%
EPS Next Y0.93%
EPS Next 2Y3.24%
EPS Next 3Y2.71%
EPS Next 5Y3.32%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-6.59%
Revenue Next Year-2.1%
Revenue Next 2Y0.04%
Revenue Next 3Y0.52%
Revenue Next 5Y1.15%
EBIT growth 1Y1.99%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year11.24%
EBIT Next 3Y3.43%
EBIT Next 5Y2.94%
FCF growth 1Y1.64%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y1.04%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%